Jointly provided by A. Webb Roberts Center for CME of Baylor Scott & White Health and CancerNet
Supported by Lilly USA, LLC and Bristol-Myers Squibb
This webcast is intended to improve care of patients with head & neck cancer by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.
This webcast is designed to meet the educational needs of medical oncologists, radiation oncologist, surgical oncologist and other health care professionals who diagnose, treat, and manage patients with head & neck cancer.
As a result of participating in the activity, learners should be better able to:
Evaluate EGFR based and other kinase targets in the treatment of squamous cell carcinoma of head and neck (SCCHN)
Evaluate the emerging immunotherapy options in the management of head & neck carcinoma
Differentiate strategies to counteracting resistance to EGFR-targeted agents in the treatment of SCCHN
Identify new options of chemo-radiation therapy and induction chemotherapy for SCCHN
Conflict Of Interest Disclosure Policy
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.
Ezra Cohen, MD Professor of Oncology University of California San Diego Moores Cancer Center San Diego, CA
Dr. Cohen discloses the following: Advisory Board: AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer
Kathryn A. Gold, MD Associate Professor University of California San Diego Moores Cancer Center San Diego, CA
Dr. Gold discloses the following: Consultant: AstraZeneca, BMS, and Genentech Advisory Boards: Ariad, Clovis, and Pfizer I will discuss off-label use of products during this presentation
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Ezra Cohen, MD, discloses that he is on the Adisory Board for AstraZeneca, Bristol-Myers Squibb, Merck, and Pfizer
Kamatham A. Naidu, PhD (CancerNet), has no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for CME of Baylor Scott & White Health and MedNet. The A. Webb Roberts Center for CME of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.
The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
It is the policy of the A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care System, Dallas to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
NON-ENDORSEMENT OF PRODUCTS The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health, Dallas do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
There are no fees for participating in or receiving credit for this webcast. During the period November 15, 2016 through November 15, 2017, participants must read all of the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
To obtain credit, a score of 80% or above on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CME Provider at 214-820-2317.
A. Webb Roberts Center for CME of Baylor Scott & White Health observes privacy and confidentiality of CME information and personal information of CME participants. Third parties receive only aggregated data about CME activities that are relevant to their interests and/or the activities they support.